Top Midday Decliners

MT Newswires Live06-29

Morgan Stanley halved Accolade's (ACCD) price target to $6 from $12 while keeping its equal-weight stock rating.

Truist adjusted its price objective to $9 from $14 but maintained the buy rating.

Late Thursday Accolade reported narrower-than-expected fiscal Q1 loss and higher-than-forecast sales. Its guidance for Q2 and full-year sales missed the average analyst estimates compiled by Capital IQ.

Shares sank 42.6%, with intraday trading volume at more than 9.9 million versus a daily average of about 724,000.

Nexalin Technology (NXL) shares sank 39% amid heavy trading after the company said overnight that it priced a public offering of 3 million shares at $1.75 apiece, for gross proceeds of roughly $5.3 million.

More than 3.87 million shares traded intraday compared with a daily average of about 2.87 million.

Wedbush Securities cut Nike's (NKE) price target to $97 from $115 while maintaining its outperform rating after "very choppy" fiscal Q4 earnings.

Shares dropped more than 20% as intraday trading volume soared to over 96.4 million versus a daily average of about 9.21 million.

Price: 3.67, Change: -2.72, Percent Change: -42.58

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment